Showing results (51-60 of 85) with videos related to
Sort By:
Pageof 9
Cancer Chemotherapy and Pharmacology|October 20, 2021
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignanciesAntoinette R Tan, Nancy Chan, Brian F Kiesel, et al.Oncotarget|April 10, 2023
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850Kristen R Spencer, Daniella E Portal, Joseph Aisner, et al.Journal of Translational Medicine|April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.Cancer Immunology, Immunotherapy : CII|February 6, 2019
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinomaSandra P D'Angelo, Matthias Hunger, Andrew S Brohl, et al.Nature|November 16, 2018
Autophagy maintains tumour growth through circulating arginineLaura Poillet-Perez, Xiaoqi Xie, Le Zhan, et al.Nature|December 8, 2018
Author Correction: Autophagy maintains tumour growth through circulating arginineLaura Poillet-Perez, Xiaoqi Xie, Le Zhan, et al.JCO Precision Oncology|June 29, 2018
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid TumorsAnshuman Panda, Anil Betigeri, Kalyanasundaram Subramanian, et al.JAMA Network Open|August 3, 2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected MelanomaRachel S Goodman, Aleigha Lawless, Rachel Woodford, et al.Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.Journal for Immunotherapy of Cancer|May 17, 2020
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trialSandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, et al.Pageof 9